The goal of this research study is to test a new study treatment for a specific type of stomach cancer. It is focused on people whose tumors are CLDN18.2 positive, PD-L1 positive, and HER2 negative. This new study treatment has 3 parts: 1. A study drug called zolbetuximab 2. Another study drug called pembrolizumab 3. Standard chemotherapy (mFOLFOX or CAPOX) Researchers want to know if this combination is safe and if it works better than current treatments for people living with this specific type of stomach cancer
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Ashwin Somasundaram
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Colorectal)
25-0880